Abbott Laboratories
ABT · What the business does, what can go wrong, and how options sellers approach it
What it does
Abbott Laboratories is a global healthcare company that makes medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products include heart devices such as pacemakers and stents, continuous glucose monitors for people with diabetes, infant formula and adult nutrition drinks, diagnostic equipment, and neuromodulation devices for chronic pain and movement disorders.
How it makes money
Abbott sells products to hospitals, clinics, laboratories, pharmacies, retailers and consumers. Medical devices and diagnostic systems often create repeat revenue, since sensors, test kits and consumables must be bought again and again. Nutrition products are sold through stores and healthcare channels. A large share of sales comes from outside the United States, so currency moves and local healthcare policies matter.
Why investors own it
Investors often view Abbott as a diversified healthcare business with exposure to long-term trends such as aging populations, chronic disease management and demand for diagnostics. Its mix of devices, diagnostics and nutrition can spread risk across different markets. It has also long paid a dividend and is a familiar large-cap name in the S&P 500. None of this guarantees future results.
What can go wrong
- Diagnostics demand can swing sharply, especially for testing tied to outbreaks.
- Product recalls, safety problems or manufacturing issues can hurt sales and reputation, particularly in infant formula and implantable devices.
- Regulators, insurers and government payers can change approvals, coverage or pricing.
- Competitors in glucose monitoring, cardiovascular devices and diagnostics are well funded and innovate quickly.
- Foreign currency swings and international exposure can affect reported results.
- Litigation and product liability claims are an ongoing risk in healthcare.
What to watch
- Organic sales growth by business segment
- Adoption and growth of continuous glucose monitoring products
- Regulatory approvals and product launches in devices
- Diagnostics sales trends
- Gross and operating margins
- Recall notices and regulatory actions
- Dividend and cash flow trends
Options income angle
Options on ABT are generally liquid, especially near the money and in monthly expirations, though thinner at far-out strikes. Implied volatility tends to rise ahead of quarterly earnings, around product or regulatory news, and during broad market stress. It typically sits lower than for many growth stocks, so premiums are often modest. One caution for premium sellers: a sharp move after earnings or safety news can gap the shares, leaving a put seller obligated to buy shares at a strike price well above the new market price.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 20, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Abbott grew sales and widened its operating margin in 2025, led by Medical Devices, while Diagnostics and Nutritional Products lagged. The bigger development is the pending purchase of Exact Sciences, which the company plans to fund with approximately $20 billion of borrowings, on top of consolidated indebtedness of approximately $12.9 billion at year end.
How the business did
- Total net sales rose 5.7 percent in 2025. The operating margin profile (operating profit as a share of sales) rose to 18.2 percent from 16.3 percent in 2024, which management credits to margin improvement initiatives, partly offset by foreign exchange and inflation.
- Medical Devices drove growth, with sales up 11.9 percent excluding foreign exchange. Continuous glucose monitoring sales totaled $7.6 billion in 2025 against $6.4 billion in 2024.
- Diagnostics sales fell 4.5 percent excluding foreign exchange. COVID-19 testing sales were $297 million, down from $747 million in 2024, and China was difficult because of volume-based procurement programs. Nutritional Products was flat, with price increases offset by lower U.S. volumes.
- Net cash from operating activities was $9.6 billion, up from $8.6 billion. Dividends paid were $4.1 billion, the quarterly dividend rose to $0.63 per share from $0.59, and the company repurchased 4.8 million shares for $604 million.
- Management flagged restructuring charges of $274 million for severance and other costs, and approximately $610 million of tax expense tied to a deferred tax asset recognized as a non-cash benefit in a prior year.
Risks specific to this company
- Exact Sciences financing. The company has a 364-day bridge loan commitment of up to $20.0 billion as back-up financing. The filing warns that more debt could hurt its credit ratings (AA- at S&P, Aa3 at Moody's), raise borrowing costs and reduce flexibility. Closing still needs Exact Sciences shareholder approval and regulatory clearances.
- Tax disputes. The IRS has issued deficiency notices covering 2017 through 2020, including $417 million for 2019 and $443 million for 2020. Malaysian authorities assessed $413 million, which a Penang High Court upheld in October 2025. The company calls the positions without merit and is contesting them.
- Reliance on sales outside the U.S. About 61 percent of net sales come from outside the U.S., exposing the company to currency swings and tariffs. Higher costs, including tariffs, partly offset the 2025 gross margin gain.
- Rebate exposure. 44 percent of gross revenues were subject to rebates and allowances, mostly in Nutritional Products and Diabetes Care. A one-percentage point rise in the rebate rate would cut net sales by approximately $225 million.
- Manufacturing and regulation. Some products rely on third-party manufacturers and single suppliers. The filing recalls the February 2022 infant formula recall at its Sturgis, Michigan facility and the May 2022 consent decree with the FDA.
- Diagnostics weakness. Rapid Diagnostics sales fell 18.0 percent excluding foreign exchange as COVID-19 demand faded.
What management is watching
- Completing the Exact Sciences deal, which management says would let the company enter cancer diagnostics at $105 per share in cash.
- R&D spending, targeted at approximately 7 percent of total Abbott sales in 2026, with a focus on rhythm management, electrophysiology, structural heart and diabetes care devices.
- Segment priorities: the Alinity diagnostic instrument line, recently launched devices, new nutrition products, and biosimilars in emerging markets.
- Debt and cash: approximately $3.0 billion of debt matures in 2026. Management expects to keep an investment grade rating and expects operating cash flow to exceed capital expenditures and dividends.
- Tax and legal items, including the IRS and Malaysia cases and OECD minimum tax rules. The OECD's January 5, 2026 guidance, once enacted, exempts U.S.-parented groups from the Pillar 2 minimum tax.
Follow ABT in Kortex
The Kortex app shows ABT's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.